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ABSTRACT
Metanephrines (MNs; normetanephrine (NMN), metanephrine (MN) and 
methoxytyramine (MT)) detected in urine or plasma represent the best biomarker 
for neuroblastoma (NB) diagnosis, however the metabolism of both catecholamine 
(CAT) and MNs remains enigmatic in NB. Using patient-derived xenograft (PDX) 
models derived from primary NB cells, we observed that the plasma levels of MNs in 
NB-PDX-bearing mice were comparable as in patients. Interestingly, murine plasma 
displayed an elevated fraction of glucuronidated forms of MNs relative to human 
plasma where sulfonated forms prevail. In tumors, the concentration ranges of MNs 
and CAT and the expression levels of the main genes involved in catecholamine 
metabolism were similar between NB-PDX and human NB tissues. Likewise, plasma 
and intratumoral profiles of individual MNs, with increased levels of MT and NMN 
relative to MN, were also conserved in mouse models as in patients. We further 
demonstrated the downregulation of the Phenylethanolamine N-Methyltransferase 
gene in NB biopsies and in NB-PDX explaining this biochemical phenotype, and giving 
a rational to the low levels of epinephrine and MN measured in NB affected patients. 
Thus, our subcutaneous murine NB-PDX models not only reproduce the phenotype of 
primary NB tumors, but also the metabolism of catecholamine as observed in patients. 
This may potentially open new avenues in preclinical studies for the follow up of novel 
therapeutic options for NB through the quantification of plasma MNs.
INTRODUCTION
NB is an embryonic tumor of the sympathetic 
nervous system, that can arise at any site of the sympathetic 
chain but most frequently in the abdominal region [1, 
2]. NB represents approximately 5% of all childhood 
malignancies, but accounts for 12% of childhood cancer-
related mortality [3]. Metastases frequently occur in NB 
with an incidence of around 70% of cases [4] and 50 to 
60% of high-risk NB will display relapse [2]. 
Catecholamine (CAT; E: epinephrine, NE: 
norepinephrine and DA: dopamine) production takes mainly 
place in adrenal chromaffin cells and sympathetic nerves. 
CAT are synthesized from L-tyrosine, which originates 
from diet and from hydroxylation of phenylalanine in the 
liver. L-tyrosine is transformed into dihydroxyphenylalanine 
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(DOPA) by the cytoplasmic enzyme tyrosine hydroxylase 
(TH). DOPA is then transformed in the cytoplasm into DA by 
the enzyme aromatic L-amino acid decarboxylase (AADC) 
[5]. In chromaffin cells, DA is internalized into neurosecretory 
vesicles by the vesicular monoamine transporters (VMAT1, 
and VMAT2, respectively SLC18A1 and SLC18A2) where 
it is converted into NE by dopamine beta-hydroxylase (DBH) 
and NE could be further converted into E in neurosecretory 
vesicles containing Phenylethanolamine N-Methyltransferase 
(PNMT) [5]. Following sympathetic stimulation, CAT stored 
in vesicles are exocyted in the blood stream to reach their 
target receptors and initiate the classically described “fight or 
flight response” [6]. A small proportion of CAT that leak from 
neurosecretory vesicles is transformed into metanephrines 
(MNs; normetanephrine (NMN), metanephrine (MN) and 
methoxytyramine (MT)) by the enzyme COMT (catechol 
O-methyltransferase) [5]. MNs diffuse freely across the 
membrane and are released in the bloodstream. A large amount 
of MNs is transformed through multiple steps involving other 
intermediate products into vanillylmandelic acid (VMA, from 
MN and NMN) and homovanillic acid (HVA from MT). These 
two end-stage are then filtered by kidneys to be secreted in 
urine [5, 7, 8]. Studies involving the enzymes responsible for 
CAT synthesis in NB compared with healthy adrenal medulla 
have been scarce, with the majority of studies focusing on 
pheochromocytoma and paraganglioma (PHEO/PGL) two 
other neuroendocrine tumors secreting MNs. CAT metabolism 
in PHEO/PGL has been extensively reviewed elsewhere [5, 
8]. The large amount of CAT found in tumors and in plasma 
has been shown to be a consequence of the over-expression of 
several enzymes involved in CAT synthesis [9, 10].
The biological bases of CAT and MNs metabolism 
remain enigmatic in patients affected by NB. NMN and 
especially MT have recently been described as new 
biomarker of NB in plasma and urine [11, 12] with better 
sensibility and sensitivity compared with CAT and VMA 
and HVA, the classical metabolites used for NB screening 
in urine of suspected patient. High MNs concentration 
in plasma arise from a high synthesis of CAT [5, 8] and 
are suspected to directly arise from NB, as extensively 
described for PHEO/PGL. However, NB biopsy availability 
is a limitation, precluding large-scale molecular studies to 
decipher CAT metabolism in these tumors. In this study, we 
validated the use of murine NB patient-derived xenografts 
(PDX) as a pertinent model to mimic NB from patients and 
we demonstrated that the noradrenergic phenotype of NB 
is due to PNMT downregulation.
RESULTS
Murine MNs are mainly found as glucuro 
conjugates forms
In this study, we used PDX derived from seven high-
risk stage M NB patients (Table 1). Four NB-PDX models 
were previously published by our group [13]. In addition, 
we developed four novel NB-PDX models from either NB 
cells disseminated in the bone marrow (BM) (for three 
patients NB11, NB13, NB14) or from the primary tumor of 
the NB-1 patient (from which a NB-PDX derived from BM 
metastatic cells was previously described [13]) (Table 1). 
To validate our novel NB-PDX models, the histological 
phenotype and the genomic profiles of the xenografts were 
analyzed. H&E and IHC staining for Phox2b, TH, DBH, 
synaptophysin (SYP), and CD56 confirmed that our novel 
NB-PDX displayed a histological phenotype comparable 
to NB primary tumors and previously published NB-PDX 
(Supplementary Figure 1A). In addition, examination 
of genomic copy number alterations (CNA) by single-
nucleotide polymorphism (SNP) array of the novel 
NB-PDX indicated that the overall genomic profile of 
segmental chromosomal alterations (SCA) was conserved 
between the primary tumor and the PDX generated from 
the corresponding patient, although several additional SCA 
were observed in 3 out of 4 PDX (Supplementary Table 1). 
These data indicated that genetically and phenotypically 
our NB-PDX mimic human NB and may represent relevant 
in vivo models for the study of CAT metabolism in NB. 
We then investigated and compared the 
concentration of MNs in the plasma of NB patients and 
NB-PDX-bearing mice. We first measured the amounts 
of free, sulfonated and glucuronidated forms of plasma 
MNs as conjugation (sulfonation or glucuronidation) 
represents a major pathway for CAT and MNs inactivation 
and besides enabling renal clearance [14]. We observed 
in patients with NB (n = 22) a large proportion of 
sulfonated MNs compared with free and glucuronidated 
forms (Figure 1A), corresponding respectively to 
94.1%, 4.4% and 1.5% of total MNs (sum of free, 
sulfonated and glucuronidated forms) (Figure 1B). This 
contrasts with MNs in murine plasma (n = 5) where 
MNs are found in majority as glucuronidated forms 
(Figure 1A), representing 81.5% of total MNs, while 
free MNs forms were less abundant (16.2%), and an 
even smaller proportion of sulfonated forms 2.3% was 
detected (Figure 1B). Considering the large differences 
in sulfonation and glucuronation, we thereafter quantified 
plasma total MNs in mice as the sum of free, sulfonated 
and glucuronidated forms. For the human samples, as 
plasma MNs concentrations described in this study for 
controls represent clinical values which lack measurement 
of glucuronidated forms of MNs, glucuronidated forms of 
MNs showed in Figure 1 were subsequently omitted for 
NB patients to ensure relevant comparisons of total MN, 
NMN and MT levels between patients and controls. This 
has however no impact as glucuronidated forms represent 
only 1.5% of total MNs in plasma. It is noteworthy that 
quantification of MNs in tissue represents free forms since 
no conjugated forms are produced within tumor tissues or 
control adrenal glands as described in PHEO/PGL ([5] and 
from our own observation during MNs quantification in 
NB tumors from patients and NB-PDX).
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MT and NMN represent NB biomarkers in the 
plasma of NB-PDX-bearing mice similarly to NB 
patients
Then we assessed whether our NB-PDX models 
were mimicking NB in patients regarding MNs 
concentration and profile in plasma. To note CAT (DA, NE 
and E in the order of synthesis) are transformed by COMT 
into MT, NMN and MN, respectively (Figure 2A) and 
NB are characterized by an elevated amount of MT and 
NMN in plasma and urine [5, 15]. As observed in patients 
affected by a NB compared to healthy human subject, 
MT and NMN plasma concentrations in PDX mice were 
significantly increased compared with healthy mice (geo. 
mean at 161.9 nmol/l vs 63.2 nmol/l and 55.4 nmol/l vs 
29.1 nmol/l respectively, *p = 0.0317 for both comparison) 
(Figure 2B, left panel). As expected, MN concentration 
was not significantly different between NB-PDX-bearing 
mice and controls (7.1 nmol/l vs 10.6 nmol/l) (Figure 2B, 
left panel). Even though plasma CAT concentration does 
not represent a reliable biomarker for the presence of a 
NB, DA is clearly increased in PDX mice compared with 
control (8.4 nmol/l vs 2.6 nmol/l, but without reaching 
significance threshold p = 0.07), whereas no significant 
differences for E (14.8 nmol/l vs 17.2 nmol/l) were 
measured; however a trend was also observed for NE: 56.7 
nmol/l vs 37.3 nmol/l p = 0.2 (Figure 2B, right panel). 
This is in agreement with CAT levels quantified in patients 
(Figure 2B, right panel). Interestingly, a deeper analysis of 
the plasma MNs profile in human and mice revealed that 
MN level is very low compared to MT and NMN both in 
NB patients (geo mean 4.83 nmol/l vs 42.14 and 127.9 
and nmol/l, respectively) and NB-PDX-bearing mice (geo 
mean 7.05 nmol/l vs 160.8 and 54.30 nmol/l, respectively) 
(Figure 2C). This is consistent with the fact that both MT 
and NMN represent biomarkers of NB in both urine and 
plasma [11, 12].
NB-PDX and human primary NB displayed 
no differences for CAT and MNs tissue 
concentration 
The intratumoral levels of CAT and MNs were then 
quantified in NB-PDX and NB biopsies (indicated in 
Table 1 and in Supplementary Table 2). Metabolites levels 
were present in low amounts in most of the tissues tested 
with concentrations close to the limit of quantification (0.01 
nmol/g of tissue) for several samples and particularly for 
MN in NB-PDX. We detected comparable levels of each 
metabolite between both tumor groups without significant 
differences (Figure 3A), except for MN levels (geo mean 
at 0.02 and 0.01 nmol/g for respectively NB and NB-
PDX for which most of the values were close or under 
the limit of quantification). We then compared MNs and 
CAT intratumoral profiles of NB primary tumors and NB-
PDX relative to murine adrenal controls, as human adrenal 
samples were not available for this analysis. In the adrenal 
glands, the major forms of metabolites are E, NE, MN 
and NMN, while DA the early product of catecholamine 
metabolite synthesis and MT represent minor forms 
(Figure 3B). Interestingly, a profile distinct from the adrenal 
controls was observed in NB and in NB-PDX tumors, as 
weaker amounts of intratumoral E and MN were detected 
relative to NE and NMN (geo mean in nmol/g: E: 0.12 and 
MN: 0.02 vs NE: 3.63 and NMN: 0.21 for NB; and E: 0.19 
and MN: 0.01 vs NE: 1.23 and NMN: 0.15 for NB-PDX) 
(Figure 3B). We refer to this profile as noradrenergic since 
E and MN synthesis are strongly reduced in NB tissues. 
This is consistent with the plasma MNs profile observed in 
the plasma of patients and mice (Figure 2C).
Table 1: Clinical and biologic characteristics of NB samples and indication of the analyses carried 
out for each NB-PDX in this study
Primary tumors NB-PDX Analyses performed with NB-PDX

















NB1* M 10 mo HR M no amp NB1-T-1 primary tumor yes yes yes yes yes yes
NB1-BM-5 BM (diagn)* yes n.d. n.d.** yes yes n.d.
NB2* F 44 mo HR M no amp NB2-BM-4 BM (diagn)* yes n.d. n.d.** yes yes n.d.
NB4* M 143 mo HR M no amp NB4-BM-8 BM (relapse)* yes n.d. yes yes n.d. yes
NB5* M 24 mo HR M amp NB5-BM-1 BM (diagn)* yes n.d. n.d.** yes yes n.d.
NB11 M 28 mo HR M amp NB11-BM-1 BM (diagn) yes yes yes yes yes yes
NB13 M 33 mo HR M amp NB13-BM-1 BM (diagn) yes yes yes yes yes yes
NB14 F 48 mo HR M amp NB14-BM-1 BM (diagn) yes yes yes yes yes yes
NB1 to NB14 correspond to NB patients. T, tumor; BM, bone marrow; F, female; M, male; mo, month; HR, high–risk group; amp, amplified MYCN locus; no amp, no amplification 
of MYCN locus, n.d., not done. NB cells were isolated from primary tumor (-T) or bone marrow aspirations (-BM) and cultured in vitro for few passages before subcutaneous 
injection into athymic Swiss nude mice. The number of in vivo passages in PDX are indicated at the end of the PDX name. *Published in [13]; **CAT/MNs evaluation in plasma 
not performed, as the plasma were not collected from these mouse models at the time at which we sacrificed the mice for the study described in [13]. 
Oncotarget52www.oncotarget.com
The noradrenergic phenotype of NB results from 
the downregulation of PNMT expression in NB
To validate further our murine NB-PDX models, 
we analyzed the expression levels of the main genes 
involved in catecholamine metabolism by real-time qPCR 
in NB-PDX and NB biopsies (indicated in Table 1 and 
Supplementary Table 2). Similar mRNA expression levels 
of TH, DBH, AADC, PNMT, MAOA, VMAT1 and NET 
were observed between human primary NB and NB-PDX, 
although a reduction of COMT and VMAT2 expression 
was measured in NB-PDX biopsies (Figure 4A). Using 
the R2: Genomics Analysis and Vizualization Platform 
(http://r2.amc.nl), we compared the expression levels of 
CAT genes between four datasets of NB primary tumors 
and a panel of adrenal glands (Supplementary Figure 2). 
TH was not significantly different between the two tissues, 
conversely to a strong upregulation for DBH, AADC, 
MAOA, VMAT2 and NET (p < 0.0001 for all comparison) 
in NB compared to adrenal glands (Supplementary Figure 
2). On the other hand, COMT was downregulated in NB 
(p < 0.0001) without significant impact, considering that 
MNs are massively produced in the tumor (Supplementary 
Figure 2). In addition, PNMT, the enzyme that converts 
NE into E, was extensively downregulated in NB 
compared to normal tissue (p < 0.0001) (Supplementary 
Figure 2). This explains the noradrenergic profile observed 
in plasma and in NB tumor tissues.
PNMT protein expression was shown to be 
downregulated in NB cell lines [16]. Here we observed 
that PNMT mRNA expression level was detected at 
3.7 to 73.6 fold lower level than other enzymes mRNA 
involved in catecholamine metabolism (Figure 4A). The 
scarce expression of PNMT compared with other CAT 
metabolism genes was confirmed by the analysis of the 
SEQC and Versteeg NB transcriptomic datasets [17, 18] 
using the R2 platform (Figure 4B). To confirm this data at 
the protein level, PNMT protein expression was analyzed 
in NB tissues from patients (Supplementary Table 2) and 
NB-PDX (Table 1) by immunoblotting. This revealed 
that PNMT protein was undetectable in the NB and NB-
PDX tissues analyzed, as well as in one noradrenergic 
PHEO (P39, NE and E concentration in tissue: 14300 
and 3 nmol/g respectively). As positive controls, PNMT 
was detected in an adrenergic PHEO (P53 with 737 and 
901 nmol/g of NE and E) and in three samples of human 
adrenal medulla tissue containing chromaffin cells that 
produce PNMT (Figure 4C and 4D). 
DISCUSSION
Studies on NB biopsies suffers from a lack of 
material due to the low number of patients that undergo 
surgery procedure before treatment with chemotherapies 
and the needs of biopsy materials for pathology and 
genetic work up. In this report, we established mice 
NB xenograft models and validated their relevancy for 
the study of CAT metabolism and MNs as biomarker 
for NB detection. For this study, we took advantage of 
4 NB-PDX models previously published by our group 
[13]. In addition, we developed four novel NB-PDX 
from metastatic NB cells of three patients and from 
the primary tumor of the patient NB-1, from which we 
already published a PDX derived from metastatic bone 
marrow cells [13]. Tumors raised in mice displayed 
histological phenotype of human primary NB and similar 
Figure 1: Free, sulfonated and glucuronidated forms of MNs (MT+NMN+MN) in plasma of mice with NB-PDX (n = 
5) and NB patients (n = 22). (A) Values and geo mean ± geo SD are plotted on a logarithmic scale and analyzed with a non-parametric 
Mann Whitney test ***p ≤ 0.0001, *p = 0.019. Geo. mean in mice and human were respectively as follow: free MNs: 33.3 and 6.8 nmole/l, 
sulfonated MNs: 1.7 and 162.8 nmole/l, and glucuronidated MNs: 185.8 and 1.3 nmole/l; (B) The relative amount of free, sulfonated and 
glucuronidated forms of MNs shown in (a) were plotted in the graph as percent of total plasma MNs (MT+NMN+MN).
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genomic profiles as their corresponding primary tumors. 
However, additional SCAs were identified in the NB-
PDX, which may be explained by the fact that primary 
cells were cultivated for a short period in vitro before their 
subcutaneous injection in mice. In addition, the presence 
of chromosomal alterations differing from those identified 
in primary tumors were also described in disseminated NB 
cells in the bone marrow or using circulating tumoral DNA 
[19, 20].
The novelty of this study is the demonstration that 
NB-PDX are not only genetically and phenotypically 
similar to human primary NB, but they also recapitulated 
CAT metabolism observed in NB patients (Figure 5). 
Indeed, we demonstrated that the levels of plasma MNs 
of NB-PDX-bearing mice were increased as observed in 
NB affected patients compared to controls. In addition, 
intratumoral CAT and MNs were found in equivalent 
proportions in NB-PDX and in NB primary tumors. 
This may be explained by the fact that the expression 
levels of the main genes involved in CAT synthesis and 
metabolism were also equivalent, except for COMT 
and VMAT2/SLC18A2 genes, which displayed lower 
expression levels in NB-PDX. These genes encode for 
the protein responsible for MNs production from CAT 
and for the monoamine transporter that internalizes CAT 
into neurosecretory vesicles in the cytoplasm, respectively. 
However, these differences are obviously of minor impact 
since MNs and CAT secretion profiles were conserved 
among the two types of tumors in both plasma and tumor 
biopsies.
Our data revealed that plasma MNs are mainly 
glucuronidated in mice, while sulfonation is a minor 
pathway, conversely to MNs in human plasma where 
sulfonation is by far the main process involved in MNs 
clearance in urine. Our observations are in accordance 
with a previous report describing in healthy rat a 
proportion of 63% of glucuronidated forms of NMN [21]. 
This implies that measurement of MNs in murine plasma 
requires a deconjugation step by glucuronidase to ensure 
a complete quantification (Figure 5). 
Furthermore, we show in this report, that plasma 
and tumor tissues displayed a noradrenergic phenotype, 
as the synthesis of E and thus MN is limited in NB. 
This applies both in human and mouse NB models, 
reinforcing the validity of our NB-PDX models to mimic 
CAT metabolism found in patients. The noradrenergic 
catecholamine profile observed in NB is associated with 
the downregulation of PNMT expression, the enzyme 
responsible for E synthesis. Indeed, a very low amount 
of PNMT mRNA was detected in primary NB tumors 
Figure 2: (A) Simplified scheme illustrating CAT and MNs metabolite biosynthesis. (B) Total plasma MNs (left panel) and CAT (right 
panel) in patients with NB (n = 22) compared with controls (n = 55) and in mice with NB-PDX (n = 5) compared with control mice (n = 
4). Geo. mean for human samples in nmol/l for respectively MN, NMN and MT in NB patients: 4.83, 127.86 and 42.14; and for human 
controls: 5.17, 8.69 and 4.44. Mann Whitney test: ***p ≤ 0.0001 for both NMN and MT (tumors compared with controls). PDX MNs levels 
are reported in the text, *p ≤ 0.05. (C) Illustration of total plasma MNs in patients NB (n = 22) and PDX NB mice (n = 5), value similar as 
in (B), to compare the relative amount each individual MNs. Kruskal-Wallis multiple comparison test: ****p ≤ 0.0001, **p = 0.0027.
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and NB-PDX. Moreover, we demonstrated the lack of 
PNMT protein expression in NB tumor biopsies and in 
NB-PDX, as described only in NB cell lines in a previous 
report [16] (Figure 5). This is also in accordance with 
our former report showing that the downregulation of 
PNMT is responsible for the noradrenergic phenotype of 
a subset of PHEO compared with adrenergic PHEO [22]. 
In succinate dehydrogenase (SDH) and Von Hippel Lindau 
(VHL) related PHEO, PNMT mRNA downregulation has 
been demonstrated to arise from hypermethylation of the 
PNMT encoding gene [23, 24], similar mechanism may 
explain the noradrenergic phenotype of NB. 
The limitations of this study are mainly due to the 
fact that our cohort of NB samples used for measurement 
of CAT and MNs in plasma, in tumor tissues and for 
the generation of NB-PDX are not overlapping. While 
NB biopsies used for intratumoral concentrations were 
obtained from high-risk stage L2 and M NB, our murine 
NB models were derived only from patients with high-
risk stage M NB, which represents metastatic tumors 
associated with unfavorable prognosis. This is because 
less aggressive NB cells are not tumorigenic in athymic 
Swiss nude mice, as observed from previous work 
from our laboratory [13]. In addition, the primary NB 
cells were cultivated for a low number of passages in 
vitro before xenotransplantation, and NB-PDX harbor 
several additional SCA alterations as compared to NB 
tumors derived from the corresponding patients, which 
may affect their phenotypic characteristics or biological 
properties. Moreover, these PDX models may not fully 
reflect the exact NB microenvironment, which would have 
been reproduced in a more appropriate manner though 
orthotopic injection into the adrenal glands and/or by using 
small fragments of NB primary tumors which contains the 
Figure 3: (A) Comparison of free MNs and CAT in tumor tissue of PDX mice (n = 8) and NB biopsy from patients (n = 11). Individual 
values (nmol/g) and geo mean ± geo SD are plotted on a logarithmic scale. Values under our limit of quantification were set at 0.005 nmol/g 
which represent half of the lower limit of quantification (LLOQ). Mann Whitney test: **p = 0.0078; (B) Tissue concentration of free MNs 
and CAT in NB primary tumors (n = 11), NB-PDX (n = 8) compared with adrenal glands (ADR) of control mice (n = 4). Kruskal-Wallis 
multiple comparison test for NB and NB-PDX, Ordinary one-way ANOVA for ADR:  ****p ≤ 0.0001, ***p ≤ 0.0005, **p ≤ 0.005, *p ≤ 0.05, 
ns comparison are not shown (p > 0.05).
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additional stromal cells that represent key players in tumor 
progression [25–27]. However, despite these limitations, 
the NB-PDX models closely mimic the metabolism of 
catecholamine as observed in patients, regarding not only 
plasma levels of MNs, but also intratumoral CAT and MN 
concentrations, as well as mRNA expression levels of 
gene involved in CAT metabolism. Slight differences in 
gene expression were recorded for COMT and VMAT1, 
however without significant impact in terms of CAT and 
MNs production pattern. In addition, NB-PDX displayed 
a noradrenergic profile with reduced level of E and NM 
relative to NE and NMN, which was shown to correspond 
to the most frequent CAT profile in NB patients [16].
Plasma MNs quantification is on the rise to 
become the gold standard for NB diagnosis, since the test 
performance is better in terms of specificity and sensitivity 
than commonly used measurements of urinary CAT, VMA 
and HVA concentrations [11, 12, 28]. Plasma MNs level has 
been shown to correlate with tumor size in PHEO/PGL [29] 
and plasma MNs (totals forms) decrease within two days 
after PHEO/PGL resection [30]. Therefore, levels of MNs in 
mice models are also very likely to reflect the progression of 
tumor. Several models of NB in mice have been established 
[25, 27]. Apart from deciphering the molecular and genetic 
aspects of the tumors, as PNMT downregulation described 
in this report, NB preclinical models are also widely used 
for the assessment of new treatment strategies [25, 27]. 
However, the evaluation of the effects of therapeutics is 
essentially based on the observation of the tumor’s size 
through diverse monitoring methods (e.g., bioluminescence 
imaging, echography, micro-PET scan) requiring repeated 
anesthesia for a time-course follow-up. It would be 
interesting to evaluate if the measurement of plasma MNs 
may be relevant to monitor the therapeutic impact of drugs 
on NB-PDX models. Indeed, the low amount of plasma 
needed for MNs quantification by HPLC MS/MS (approx. 
50 μl) is perfectly compatible with repeated blood collection 
in living mice without anesthesia. Thus, measuring plasma 
MNs at repeated time points (e.g., once a week) after the 
administration of drugs represents a less invasive method, 
which would allow implementing the principles of the 
3Rs (Replacement, Reduction and Refinement) in animal 
experimentation. 
To summarize, our NB-PDX model could represent 
a valuable tool for the study of catecholamine metabolism 
in NB and potentially for preclinical drug screening for 
NB therapy since previous studies have demonstrated 
a correlation between tumor size and metanephrine 
concentration. Blood testing of mice for metanephrine 
levels could therefore represent an option to monitor the 
growth of the tumors with limited impact on the animal 
welfare.
Figure 4: (A) mRNA expression levels of the main genes involved in CAT metabolism were analyzed by real-time qPCR in primary NB 
(n = 11) (black circles) and in NB-PDX (n = 7) (white circles). Data are plotted as mRNA expression level relative to the control genes 
TBP, GAPDH and EEIF1A1 with geo means ± geo SD (Mann Whitney test: COMT p = 0.0003, VMAT2 p = 0.0041, ns comparisons (p > 
0.05) are not shown). qPCR analyses were performed in triplicats. (B) Illustration of the mRNA expression levels (normalized expression, 
in log2) of the indicated genes in two NB transcriptomic datasets analyzed by RNAseq (left) and microarrays (right). (C) Immunoblotting 
analysis of PNMT in representative tissues of three samples of adrenal gland tissue containing chromaffin cells, 2 PHEO, 3 NB and 5 NB-
PDX. β-actin was used as loading control. (D) Densitometric quantification of immunoreactive band densities of Figure 4C using the Image 
J software (https://imagej.nih.gov/ij/download.html). The relative expression (PNMT/β-actin ratio) is plotted on the graph. 
Oncotarget56www.oncotarget.com
MATERIALS AND METHODS 
NB, adrenal glands and PHEO/PGL tissues 
PHEO/PGL samples were carefully chosen to be 
devoid of remaining healthy adrenal tissue by the surgeon 
or the pathologist. Similarly, healthy human adrenal 
glands were collected from the same procedure when 
healthy tissue was available and clearly distinct from 
the tumoral piece. The NB tumor material was collected 
from patients with stage L2 and M NB diagnosed at the 
Hemato-oncology Unit of the University Hospital of 
Lausanne (Switzerland) enrolled in the HR-NBL1 study 
from SIOPEN, after informed consent and in agreement 
with local institutional ethical regulations. This study was 
approved by the local ethics committee for the Canton de 
Vaud (Reference number: 2017-01865, 95/04 and 26/05). 
Of note the cohort of NB patients used for intratumoral 
CAT and MNs analyses and for the generation of NB-PDX 
are not overlapping.
NB primary cells were derived from high-risk 
stage M patients. Cells from the primary tumor of the 
NB1 patient were isolated as described [13]. Briefly, 
the tumor fragment was dissociated in a single-cell 
suspension by mechanical dissociation in phosphate-
buffered saline containing 0.01 mg/ml collagenase II 
(Invitrogen, Carlsbad, CA, USA) and 0.1 mg/ml DNaseI 
(Roche Diagnostics, Basel, Switzerland) for 30 minutes 
at 37°C, followed by filtration through CellTricks (50 
μm; Partek, Inc, St Louis, MO). NB primary cells derived 
from all other patients were isolated from involved 
BM. One volume (vol.) of BM was diluted with 3 vol. 
of Dubelco’s modified Eagle’s medium (D-MEM) (Life 
Technologies, Zug, Switzerland) and deposited on 2 
vol. of Ficoll-Plaque Plus (GE Healthcare Europe) and 
centrifuged for 30 min at 1600 rpm. Then mononuclear 
cells were collected at the interphase, cells were washed 
twice in PBS and platted in neural basic medium (DMEM/
F12 supplemented with penicillin/streptomycin, 2% B27 
[Invitrogen], human recombinant basic fibroblast growth 
factor [FGF; 20 ng/ml; Peprotech, Rocky Hill, NJ], and 
EGF [20 ng/ml; Peprotech]). Once established, the purity 
of NB primary cells was then verified by performing anti-
GD2 immunostaining. Primary NB cells NB1-T, NB1-BM 
and NB11-BM were also validated by IHC staining for 
Phox2b and SYP (Supplementary Figure 1B). The primary 
cells generated from the other patients were not evaluable 
by this method before implantation in mice.
NB xenografts
All in vivo procedures were performed under the 
guidelines of the Swiss Animal Protection Ordinance 
and the Animal Experimentation Ordinance of the Swiss 
Federal Veterinary Office (FVO). Animal experimentation 
protocols were approved by the Swiss FVO (authorization 
number: VD2995 and VD3372). All reasonable efforts 
were made to reduce suffering, including anesthesia for 
painful procedures. 
All PDX were generated using NB cells isolated 
from either a primary tumor (NB1-T) or from bone marrow 
aspirations and maintained in vitro for a limited number 
Figure 5: Graphical summary of our findings described in this report, as discussed in the results and discussion 
sections. This graphic was created using the software from Biorender (https://biorender.com/). 
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of passages (< 5). The only exception is the NB4-BM-8 
PDX, which was generated from frozen cells dissociated 
from the seventh passage in vivo of the NB4-BM model 
(ie. NB4-BM-7). Primary NB cells (0.8 × 106 to 2 × 106) 
cells were suspended in 200 µl of Dulbecco modified 
Eagle medium DMEM (Invitrogen, Luzern, Switzerland) 
and BD Matrigel Basement Membrane matrix (1:1; 
BD Biosciences, San Diego, CA, USA) and implanted 
subcutaneously (s.c.) in the flanks of athymic Swiss nude 
mice (Charles River Laboratories, France). Tumor growth 
was followed up using calipers every 3 days. Mice were 
sacrificed once tumors reached a volume of approx. 900 
mm3. NB-PDX were then maintained in vivo by serial 
subcutaneous transplantations. Tumor fragments were 
split into pieces for paraffin-embedded tissue formation, 
or collected in perchloric acid 0.1M for CAT and MNs 
quantification, or snap frozen in liquid nitrogen for 
protein or RNA extraction. NB xenograft fragments 
were also dissociated using the Tumor Dissociation kit 
Mouse (Miltenyi Biotec GmbH, Germany) according to 
manufacturer’s instructions, followed by filtration through 
CellTricks (50 μm; Partek, Inc, St Louis, MO, USA) and 
dissociated cells were frozen in cryo-preservative medium 
(50% DMEM, 40% FCS and 10% DMSO). 
Plasma collection
The control plasma were derived from 55 patients 
that were not affected by a NB, since the plasma MNs 
values were bellow upper reference limit. These patients 
were under 15 years of age, without previous MNs or 
CAT measurements request and none of them had MNs 
and CAT quantified ever since. For plasma from NB 
patients, a random set of 22 plasma was analyzed. The 
patients from which NB tissues were used to establish 
xenograft tumors (n = 7) were not part of this cohort of 
22 patients. All blood samples were collected using a 
forearm venous cannula, with the patient kept supine for 
at least 15 min before sampling. Patients were instructed 
to fast and to abstain from caffeinated beverages for 24 
hours before blood collection. All samples were collected 
onto ice and centrifuged within 30 min after puncture 
at 2500 g for 10 min at 4°C. Plasma was kept at −80°C 
until analysis. Total MNs and MT were desulfated using 
perchloric acid method or treated with sulfatase as 
described in a previous study [31]. Total and free MNs 
and MT were extracted on µElution plate and quantified 
by ultraperformance liquid chromatography-tandem mass 
spectrometry (UPLC-MS/MS) [32, 33]. The method used 
for free and total MNs quantification is identical after 
the deconjugation treatment applied to the sulfated MNs 
and MT [31]. 
For plasma collection from mice, immediately 
after mice sacrifice, blood was collected through heart 
puncture using 1 ml syringe (Omnifix-F, B.Braun, 
Melsungen, Germany) mounted with 25G5/8 needles (BD 
Microlance™ 3, Becton Dickinson, France). Blood was 
transferred in EDTA collection tubes BD Microtainer® 
MAP (Becton Dickinson, USA). All samples were 
collected onto ice and centrifuged within 30 min after 
puncture at 2500 g for 10 min at 4°C. Plasma was kept at 
−80°C until analysis.
CAT and MNs quantification
Tumor tissues and murine adrenal glands were 
disrupted in perchloric acid 0.1M and were sonicated 
using a Branson Sonifier 450 (Branson, Danbury, CT, 
USA) at full power for 30 seconds. CAT from tissue or 
plasma were extracted using activated alumina in 0.5 ml 
microcentrifuge tubes and quantified by ultraperformance 
liquid chromatography-tandem mass spectrometry (UPLC-
MS/MS) [34]. MNs were extracted in homogenized tumor 
tissue and plasma and quantified as previously published 
[32, 33]. 
Enzymatic hydrolysis of sulfates and 
glucuronides
Total MNs and MT were desulfated using perchloric 
acid method or treated with sulfatase as described in 
a previous study [31]. Glucuronides were removed 
enzymatically as follows: 10 µl of plasma samples were 
incubated with 90 µl of 10 mM ammonium acetate buffer 
pH 6.5 and 10 µl of beta-glucuronidase (Sigma-Aldrich, 
Buchs, Switzerland; previously dissolved in 2.5 M 
ammonium acetate buffer pH 5.5). Incubation time was 
1 h at 37°C with agitation at 650 rpm. Samples were then 
diluted 2X in 10 mM ammonium acetate pH 6.5 and MNs 
were extracted as described above.
RNA extraction and real-time qPCR
RNA extraction was performed using Trizol 
(Invitrogen, Luzern, Switzerland) or RNAeasy kit 
with DNaseI treatment according to manufacturer’s 
instructions (Qiagen, Hombrechtikon, Switzerland), and 
cDNA synthesis was performed using the PrimeScriptTM 
RT reagent Kit (Takara Bio Inc, Japan). Real time PCR 
assays were conducted in 384 wells using Sybergreen 
(Roche, Basel, Switzerland) with an Applied Biosystems 
7900HT SDS (Thermo Fischer Scientific, Reinach, 
Switzerland). Negative controls were performed on the 
same amount of total RNA without adding the reverse 
transcriptase (NEC, no enzyme control). All primer 
pairs, chosen with the primer designing tool from the 
National Center for Biotechnology Information (NCBI) 
(Supplementary Table 3), were tested on a cDNA dilution 
series with efficiency comprised between 1.9 and 2.0. 
qPCR parameters were: 95°C 10 min, 40 cycles 95°C 15 
sec. 60°C 1 min and melting curves were as expected in 
all cases. Normalization of gene expression was performed 
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on the three reference genes (RG) TBP, GAPDH and 
EEIF1A1 using the ∆Ct method with Ct_RG = (Ct_
TBP+Ct_GAPDH+Ct_EEIF1A1)/3 and mRNA expression 
level = 2-(Ct_Gene-Ct_RG). 
Immunoblotting
Adrenal glands remaining from PHEO surgery 
were used to obtain human adrenal medulla tissues. This 
was separated from the adrenal cortex using a scalpel by 
scraping off the brown interdigitated islets of chromaffin 
cells from adrenal glands. Tumor tissues and healthy parts 
of adrenal medulla were disrupted using a micro potter 
and lysed in a lysis buffer containing PBS with 0.5% 
triton X-100 and protease inhibitor (Complete™, Roche) 
to represent 20% w/v. Samples were then sonicated 
and clarified by a short centrifugation step of 2000 g 
for 30 seconds to discard the pellets. Samples were 
fractionated by SDS-PAGE under reducing conditions 
using precast gels (Bio-Rad, Reinach, Switzerland). 
Volumes loaded were 10 µl from a 20% wt/vol extract 
for biopsies and 5 µl from a 25 cm2 plate of confluent 
cells lysed in 200 µl of lysis buffer. Proteins were 
electroblotted onto nitrocellulose membrane and probed 
with antibodies. Immunoreactive bands were revealed by 
chemiluminescence assay (PerkinElmer, Schwerzenbach, 
Switzerland). Anti-PNMT polyclonal antibody raised 
in rabbit was purchased from Abcam (Lucerna-Chem 
AG, Luzern, Switzerland, ab167427) and anti-β-actin 
monoclonal antibody (AC-15) was purchased from Sigma-
Aldrich (Buchs, Switzerland). Secondary HRP conjugated 
anti-mouse and anti-rabbit antibodies were from Bio-Rad 
(cat. number 170-6516 and 170-6515, respectively). 
Quantification of PNMT and β-actin immunorevelation 




The Hematoxylin and eosin (H&E) and 
immunohistochemistry (IHC) labeling were performed 
by the Lausanne Mouse Pathology Facility. IHC were 
performed on FFPE blocks of primary NB tumors, 
NB-PDX and cell pellets of the primary NB cells. IHC 
stainings were performed using anti-DBH Ab [9], anti-
Phox2b (B11, # sc-376997, Santa Cruz Biotechnology, 
Dallas, USA), anti-TH (MAB318, MERCK KGaA, 
Darmstadt, Germany), and anti-SYP (NCL-L-SYPAP-299, 
Novocastra™, Leika Biosystems, Newcastle, UK) and 
polyclonal rabbit Ab anti-CD56/Ncam1 (14255-1-AP, 
Proteintech, USA). 
For anti-GD2 immunocytochemistry, 200’000 
cells were spin on cytospins with an Hettich (Hettich 
Zentrifugen, Tuttlingen, Germany) centrifuge at 700 rpm 
for 5 min. Slides were air-dried overnight, then fixed in 
4% PBS-buffered paraformaldehyde for 10 min, washed 
in PBS, and incubated for 30 min at RT with monoclonal 
mouse anti-GD2 Ab (clone 7A4D8 [35]. After 3 washes in 
TBS 5 min., slides were incubated for 30 min at RT with 
rabbit anti-mouse antibody/AP (Dako, #D0314, Glostrup 
Denmark) diluted 1/30 in TBS, then with swine anti-rabbit 
Ig/AP (Dako, #D0306) diluted 1:20 in TBS for 30 min 
at RT, then with Fuchsin+ Substrate-Chromogene System 
(Dako, #K0625) for 10 min. After washing in running 
tape water for 5 min. slides were counterstained with 
hematoxylin (Sigma Aldrich, St Louis, MO, USA) and 
mounted with cover slip in buffered glycerine.
SNP array analysis
DNA was extracted from fresh or frozen NB 
(for NB-11, NB-13, and NB-14) and frozen NB-PDX 
tissues, with a tumor cell content superior to 50%, on a 
EZ1 advanced XL DNA extractor using DNA Tissue Kit 
(Qiagen Hombrechtikon, Switzerland) and quantified 
on a NanoDrop ND-2000 spectrophotometer (Thermo 
Fisher Scientific, Inc.; Waltham, MA, USA). SNP array 
analysis was performed using the Affymetrix CytoScan 
HD platform (Thermo Fisher Scientific, Inc.; Waltham, 
MA, USA) according to the manufacturer’s protocol. 
Data analysis was performed using Chromosome analysis 
suite (ChAS) version 3.1.1.27 (r9436). CNA calling was 
performed by visual inspection.
Statistics
The measurement data were explored statistically 
and graphically using Prism (v. 8.0, GraphPad Software, 
Inc. La Jolla, CA, US). Non-parametric Mann Whitney 
test was used to compare two different conditions. 
Multiple comparisons were performed by one-way Anova 
or Kruskal-Wallis test depending on data distribution. 
Only comparisons with a p-value < 0.05 were considered 
as statistically significant.
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